Here we used novel PRMT5 blockers coupled with a panel of disease specific cellular and animal models to better understand its functions and potential as a therapeutic target in ACC, emphasizing the importance of pre-selecting the patients based on their underlying molecular profile in order to improve the efficacy of the treatment. Here, PRMT5 is linked to adrenal cortex carcinoma.